EP0283474A1 - Verfahren zur herstellung einer darreichungs- und dosierungsform für arzneimittelwirkstoffe, reagentien oder andere wirkstoffe - Google Patents
Verfahren zur herstellung einer darreichungs- und dosierungsform für arzneimittelwirkstoffe, reagentien oder andere wirkstoffeInfo
- Publication number
- EP0283474A1 EP0283474A1 EP86906303A EP86906303A EP0283474A1 EP 0283474 A1 EP0283474 A1 EP 0283474A1 EP 86906303 A EP86906303 A EP 86906303A EP 86906303 A EP86906303 A EP 86906303A EP 0283474 A1 EP0283474 A1 EP 0283474A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- carrier film
- coating
- composition
- active
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000004480 active ingredient Substances 0.000 title claims description 45
- 239000002552 dosage form Substances 0.000 title claims description 18
- 239000003814 drug Substances 0.000 title abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title description 4
- 238000000576 coating method Methods 0.000 claims abstract description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000013543 active substance Substances 0.000 claims abstract description 21
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- 235000011187 glycerol Nutrition 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 239000008273 gelatin Substances 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 10
- 239000008107 starch Substances 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims description 29
- 239000008199 coating composition Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000012876 carrier material Substances 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 239000000025 natural resin Substances 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 229920003002 synthetic resin Polymers 0.000 claims description 5
- 239000000057 synthetic resin Substances 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000012042 active reagent Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 238000004080 punching Methods 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims 2
- 238000007774 anilox coating Methods 0.000 claims 1
- 230000001360 synchronised effect Effects 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 16
- 238000001035 drying Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920001592 potato starch Polymers 0.000 description 5
- 238000007639 printing Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000002864 food coloring agent Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- -1 methyl hydroxypropyl Chemical group 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000007646 gravure printing Methods 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000000596 hypostatic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000011092 plastic-coated paper Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Definitions
- Medicines can be administered orally in the form of powders, drips or juices.
- dosage forms such as tablets, coated tablets or capsules are generally preferred by the manufacturer.
- Reagents and other active ingredients e.g. Sweeteners or flavorings are often tableted for precise dosed use.
- the manufacturing technology for tablets, coated tablets, capsules and the like is largely mature, but a number of system-related disadvantages cannot be overlooked.
- film formers which are preferably water-soluble compounds such as methyl and ethyl cellulose, but especially hydroxypropyl cellulose, hydroxyethyl cellulose or methyl hydroxypropyl cellulose.
- the films can also contain fillers and release agents.
- the active substance-containing films obtained in this way can also be divided into individual sections for perforation.
- the invention is based on the object to provide a "two-dimensional" dosage and dosage form which does not have the disadvantages mentioned, can be easily manufactured and can be adapted with great flexibility to the requirements of the market and various active ingredients.
- the invention relates to a method for producing a dosage and dosage form for active pharmaceutical ingredients, reagents or other active ingredients in the form of a film with an active ingredient-containing coating, which is characterized in that
- a) produces a water-soluble carrier film from an aqueous composition based on starches, gelatins, glycerol and / or sorbitol and, if appropriate, natural and / or synthetic resins and / or gums,
- a carrier film can be used for a wide variety of active ingredients and can therefore be economically produced in large quantities
- the active ingredient-containing layer can be very thin in the case of highly effective medicinal products, since the carrier material ensures sufficient mechanical strength,
- the active ingredient-containing coating can be applied with a constant layer thickness, so that the required tolerances can be maintained,
- the carrier can be printed with various information on the front and in particular on the back using physiologically compatible printing inks,
- the dose units can be flexibly designed by appropriate pre-division, for example perforation, so that only one product has to be produced for different dosages (for example for adults and children); if necessary, the pre-division can only be carried out in the pharmacy or in the hospital according to medical information.
- the invention according to the invention also has the advantage of the extremely small space requirement in common. Instead of folding boxes, it is therefore possible, for example, to use bags or pouches made of plastic film or plastic-coated paper, into which the product is sealed, similar to moist refreshing tissues.
- the carrier film is produced in a manner known per se using a continuously operating film machine on a roll basis.
- the coating process for the production of the carrier film works on the roll principle, i.e. the water-containing composition for the carrier film is applied by means of rollers and a doctor blade and spread out into thin sheets, pre-dried on the roller and then dried to the desired final moisture in the main drying cycle.
- the end product obtained is so strong and elastic that it can be wound on rolls and can be stored if the residual moisture is not too high (risk of mold formation).
- the film width can be as desired and is advantageously tailored to the width of the coating machine. However, it is advisable to match the two widths to one another already during manufacture. It is also technically possible to carry out the film production and the coating one after the other on the same system, as a result of which the economy can be increased significantly.
- the composition used is pumped at the desired temperature, viscosity and homogeneity.
- the film is then dried in a heat tunnel.
- the carrier film obtained in this way represents the indifferent carrier for later coating with different coating compositions.
- a physiologically harmless composition is used to produce the water-soluble carrier film.
- the “water solubility” should be defined in such a way that the film is produced from an aqueous composition and that the finished film later dissolves or swells in water or in the gastric juice environment when it is used.
- Gelatins and starches are particularly suitable film formers.
- PVP poly-N-vinylpyrrolidone
- PVA polyvinyl alcohol
- Water-soluble acrylic resin dispersions can also be used.
- Suitable plasticizers are in particular polyfunctional alcohols such as glycerol and sorbitol (Karion).
- the components are mixed cold with water in a suitable manner and processed into a spreadable slime with gentle heating and constant stirring.
- the stirring in of air must be avoided as far as possible in order to obtain a clear, possibly slightly opalescent mass.
- the thickness of the carrier film is preferably between approximately 50 and 250 ⁇ m. It is largely controllable.
- the properties of the carrier film can also be greatly influenced qualitatively by a corresponding combination of the film formers and plasticizers.
- the carrier film should have a thickness that is as uniform as possible (preferably, for example, 100 ⁇ m), be slightly elastic and bendable without breaking.
- the proportion of starch should be sufficiently high so that moisture is absorbed when the coating composition is applied, without the surface sticking or the entire film softening.
- Water soluble natural and / or synthetic resins e.g. Acrylic resins and Gu me are also suitable. Possibly. other common substances can be added to the mass, e.g. Preservatives such as p-hydroxybenzoic acid esters, inert soluble or insoluble fillers, sugar or other sweeteners, other polyols, waxes or dyes.
- the possibility of front and back printing on the carrier film is a particular advantage of the dosage form according to the invention.
- the labeling, information about the ingredients and dosage information can be printed. If necessary, even Print the entire contents of a leaflet on the back, with the result that a separate leaflet, which is also often lost, becomes superfluous.
- the entire administration schedule can be applied in such a way that simple intake control is ensured.
- Physiologically compatible colors food colors
- aqueous composition which is physiologically inert and whose individual components are suitable for pharmaceuticals or foods is used for the active substance-containing coating composition. What is important is the mutual physical-chemical affinity and compatibility between coating composition and carrier film, which is always particularly good when the components used are the same or have very similar properties. Taking into account the added active ingredient, the formulation of the coating composition accordingly corresponds to that mentioned above for the carrier film, the exact adjustment to the solids content and viscosity being carried out by means of indifferent source and fillers.
- the mass thus once contains polymeric film formers, preferably gelatin and swelling or soluble starches and, if appropriate, celluloses or hemicelluloses.
- Plasticizers are also added, in particular polyhydric alcohols such as glycerol or sorbitol.
- polymeric swelling agents are used, preferably alginates, pectins, chitins, lecithins or polyethylene glycols. These latter substances can also serve as adhesion promoters.
- water-soluble synthetic or natural resins or gum or gum arabic can also be added in order to improve the adhesion of the coating to the carrier material.
- preservatives such as p-hydroxybenzoic acid esters, colorants (food colors), pigments such as titanium dioxide or flavoring and sweetening agents can be added.
- Coating compositions with a water content of approximately 50% and a viscosity of approximately 30 to 10,000 cPs have proven to be particularly suitable.
- the formulation and preparation is similar to that of a drug juice in which the active ingredient or combination of active ingredients is dissolved or evenly dispersed.
- the coating composition must have sufficient homogeneity and galenical stability so that a uniform active ingredient content of the finished coating is ensured.
- the active ingredient is dissolved or dispersed in this matrix. If a dispersion is used, the active ingredient must be extremely finely divided for uniform distribution.
- the average particle size is preferably in the range from about 1 to 20 ⁇ m.
- the dosage form according to the invention is particularly suitable for medicaments which are administered in low doses, i.e. in which the single dose for oral administration is between 0 mg (placebo) and about 20 mg.
- Suitable active pharmaceutical ingredients can be found in all areas of oral therapy; to be highlighted include Analeptics, antibiotics, antidiabetics, antiemetics, anti- epileptics, antihypertensives, corticoids, geriatrics, hypnotics, cardiacs, hypostatics and bioactive substances.
- the coating composition is normally applied to one side of the carrier film, but double-sided coating is also possible, in particular with two different active ingredients.
- Each coating can contain one or more active pharmaceutical ingredients. If, when using several active ingredients, these are not readily compatible with one another and can be contained in a coating composition, it is possible with the dosage form according to the invention to apply the coating in several layers of different composition and thereby to separate the active ingredients from one another separate, if necessary an active ingredient-free intermediate layer can be provided.
- a further protective layer over the active substance-containing layer, which protects the active substance (s) against contact with the atmosphere and / or against light. In these cases, the protective layer must accordingly be impermeable to air and moisture and / or impermeable to light by adding appropriate dyes or pigments.
- the active substance release after administration of the medicament can be controlled by an appropriate structure of the coating.
- an active substance layer between at least two further layers, which control the active substance absorption in the gastrointestinal tract in a manner known per se.
- the active ingredient layer can e.g. be arranged between two acid-insoluble layers, so that the stomach is passed through during administration and absorption occurs only in the intestinal tract.
- different active substances can be applied to the carrier film in different layers one above the other, so that the absorption takes place successively and / or with a delay.
- the carrier material is coated with the active substance-containing coating composition by means of a roller application method.
- This method which is particularly suitable for quantitative coating, works according to a method similar to gravure printing, which is referred to as "battery engraving".
- Machines suitable for this purpose are on the market (Pagendarm, Hamburg) and allow order weights of up to 80 g / m 2 at web speeds of several 100 m / min.
- the reproducible weight constancy for 20 g / m 2 is only +/- 2.5% for 1 g / m 2 and for about +/- 10% over the entire area.
- the coating composition is applied continuously via rollers with a special fine engraving, the engraved grooves preferably forming an angle of 30 to 60, in particular 45, to the running direction of the carrier film.
- 27 to 80 grooves / cm can be etched into the rollers.
- the engraving can take up a defined amount of the coating material and then pass it on to the carrier film.
- the coating quantities can be set very precisely by varying the advance speed, the running direction and the engraving, and by indirect application via a further speed-variable roller.
- a two-sided coating often offers advantages, since problems caused by discarding the carrier material and by different hygroscopicity are compensated for. Multiple and also stripe coatings, even printed image coatings, are possible and offer great variability in the processing of incompatible active ingredients.
- Another suitable application method corresponds to the coating of paper or foils.
- Raw papers are improved in that they are coated on one or both sides with coating materials.
- the aqueous coating compositions are first passed to a rolling mill, which they take up by means of a rotating roller, wiped to a defined layer thickness with a doctor blade at a certain distance, whereupon the roller dispenses the coating composition onto the carrier.
- the carrier film which can be 0.30 to 7.50 m wide, then runs through one Drying tunnel and is then wound up on rolls. This process can be repeated in one or more steps on one or two sides, and an already coated surface can also be coated again.
- the weight of the carrier material increases by that of the dry matter.
- the accuracy of the application process using this doctor blade process is reproducible at +/- 5%. It depends on the respective layer thickness, which can vary between 4 and 40 g / m 2 . Within the individual productions, a weight tolerance of less than +/- 1% per unit area can be achieved.
- each coating possibly going through a drying station beforehand.
- This can consist, for example, of a tempered pair of rollers and a drying tunnel which can be controlled in sections. After the last coating process, the coated material is wound up on rolls,
- the active substance-coated carrier film is then pre-divided into dose units, which can be separated like stamps.
- This pre-division will normally take place at the pharmaceutical manufacturer, but it is also conceivable to deliver the coated material to hospitals or pharmacies, for example, where the pre-division can then be carried out depending on the dose or also individually according to the doctor's prescription.
- the pre-division takes place in a particularly simple manner by perforation or punching, it being possible to combine this step with the printing on the carrier material. In many cases, however, it becomes cheaper be to carry out the printing of the carrier material before the coating.
- the coated carrier material Before or better after the active ingredient-containing coating has been divided into dose units, the coated carrier material is cut into ready-to-use sections which contain a certain number of dose units. It is also conceivable to cut the material on rolls into narrow strips. The individual dose units can then be separated from such a single roll in a manner similar to individual stamps.
- the invention has essentially been described above in connection with medicaments, but is in no way limited to this.
- dosage forms for chemical reagents, flavorings and the like can also be produced in the same way.
- the viscosity of the slime-like composition was approximately 3000 cPs at 50 ° C. With the help of the coating process, the mass was processed into a film which, after drying, still contained 9.3% residual water.
- the coating composition was produced in accordance with the following recipe:
- the viscosity of the slime-like composition was between 4,000 and 10,000 cPs, depending on the temperature and the active ingredient.
- the gelatin was first dissolved in a sufficient amount of water. For this purpose, water from 90 to 95 ° C was placed in that the gelatin was added with stirring. In a separate batch, the active ingredient was dissolved in water together with the glycerol. Finally, the potato starch was stirred at 50 to 60 ° C. with stirring in a sufficient amount of water. The gelatin solution and the potato starch suspension were combined and the active ingredient suspension was slowly stirred into the mixture, air pockets being avoided. The temperature was kept at 55 to 60 ° C. Finally, the desired water content was adjusted by adding more water.
- the coating composition was applied to the carrier film by means of battery engraving with a wet coating weight of 55 g / m 2 . After drying, the coating weight was 23 g / m 2, corresponding to an active ingredient content of 5 g / m 2 .
- the drug-coated film was then perforated like a box, so that the individual sections had an area of 5 cm 2 with dimensions of 2 ⁇ 2.5 cm. Such a section contained 2.5 mg of active ingredient.
- a dosage form was obtained which swells and melts rapidly in the mouth when taken orally and is accordingly easy to swallow.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3536024 | 1985-10-09 | ||
DE3536024 | 1985-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0283474A1 true EP0283474A1 (de) | 1988-09-28 |
Family
ID=6283161
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86906303A Pending EP0283474A1 (de) | 1985-10-09 | 1986-10-07 | Verfahren zur herstellung einer darreichungs- und dosierungsform für arzneimittelwirkstoffe, reagentien oder andere wirkstoffe |
EP86113919A Expired - Lifetime EP0219762B1 (de) | 1985-10-09 | 1986-10-07 | Verfahren zur Herstellung einer Darreichungs- und Dosierungsform für Arzneimittel-Wirkstoffe, Reagentien oder andere Wirkstoffe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP86113919A Expired - Lifetime EP0219762B1 (de) | 1985-10-09 | 1986-10-07 | Verfahren zur Herstellung einer Darreichungs- und Dosierungsform für Arzneimittel-Wirkstoffe, Reagentien oder andere Wirkstoffe |
Country Status (10)
Country | Link |
---|---|
US (1) | US4849246A (de) |
EP (2) | EP0283474A1 (de) |
JP (1) | JPS63501794A (de) |
AT (1) | ATE59289T1 (de) |
AU (1) | AU6541786A (de) |
CA (1) | CA1275046A (de) |
DE (1) | DE3676626D1 (de) |
ES (1) | ES2019275B3 (de) |
GR (1) | GR3001238T3 (de) |
WO (1) | WO1987002241A1 (de) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4712460A (en) * | 1985-11-18 | 1987-12-15 | Biotrack, Inc. | Integrated drug dosage form and metering system |
DE3630603A1 (de) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | Darreichungs- und dosierungsform fuer arzneimittelwirkstoffe, reagentien oder dergleichen sowie verfahren zu deren herstellung |
CH674370A5 (de) * | 1987-03-27 | 1990-05-31 | Pier Luigi Prof Dr Luisi | |
DE3727232A1 (de) * | 1987-08-14 | 1989-02-23 | Lohmann Therapie Syst Lts | Verfahren zur herstellung einer darreichungs- und/oder dosierungsform fuer arzneimittelwirkstoffe |
US5447966A (en) * | 1988-07-19 | 1995-09-05 | United States Surgical Corporation | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin |
DE59004042D1 (de) * | 1989-10-14 | 1994-02-10 | Desitin Arzneimittel Gmbh | Mund- und zahnpflegemittel. |
US5354551A (en) * | 1989-10-14 | 1994-10-11 | Desitin Arzneimittel Gmbh | Oral and dental hygiene preparation |
DE4018247A1 (de) * | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
US5451673A (en) * | 1993-04-23 | 1995-09-19 | The United States Of America As Represented By The Secretary Of Agriculture | Films fabricated from mixtures of pectin and starch |
DE4419824A1 (de) * | 1994-06-07 | 1995-12-14 | Lohmann Therapie Syst Lts | Volumen-expandierbares, als Wirkstoffträger insbesondere zur oralen Anwendung geeignete flächige Anwendungsform |
DE4419818C2 (de) * | 1994-06-07 | 1998-10-22 | Lohmann Therapie Syst Lts | Wirkstoffträger zur kontrollierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt mit verzögerter Pyloruspassage und Verfahren zur Herstellung desselben |
US5688523A (en) * | 1995-03-31 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Method of making a pressure sensitive skin adhesive sheet material |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
DE19652188C2 (de) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
DE19652257A1 (de) | 1996-12-16 | 1998-06-18 | Lohmann Therapie Syst Lts | Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform |
EP0961611B1 (de) | 1997-01-14 | 2002-03-27 | LTS Lohmann Therapie-Systeme AG | Expandierbares gastroretentives therapie-system mit kontrollierter wirkstofffreisetzung im gastrointestinaltrakt |
US6096328A (en) * | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
DE19736520A1 (de) * | 1997-08-22 | 1999-02-25 | Lohmann Therapie Syst Lts | Kennzeichnung für klebende flächenförmige dermale und transdermale therapeutische Darreichungsformen unter Verwendung eines klebenden Plfasters als Informationsträger, sowie Verfahren zu seiner Herstellung |
JP3460538B2 (ja) * | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | 速溶性フィルム製剤 |
DE19745208A1 (de) * | 1997-10-13 | 1999-04-15 | Labtec Gmbh | Mundfilm |
DE19800682B4 (de) * | 1998-01-10 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Herstellung einer Primärverpackung für film- oder oblatenförmige Darreichungsformen |
DE19837073A1 (de) * | 1998-08-17 | 2000-03-23 | Lohmann Therapie Syst Lts | Folienförmige Wirkstoffträger |
DE19900645C2 (de) * | 1999-01-11 | 2003-03-20 | Deotexis Inc | Transdermales therapeutisches System |
US6231957B1 (en) * | 1999-05-06 | 2001-05-15 | Horst G. Zerbe | Rapidly disintegrating flavor wafer for flavor enrichment |
EP1200064B1 (de) | 1999-07-02 | 2003-05-02 | The Procter & Gamble Company | Zusammensetzungen zur freisetzung von mundpflegewirkstoffen enthaltend organosiloxan harze durch verwendung eines wiederablösbaren trägerstreifens |
DE10008165A1 (de) | 2000-02-23 | 2001-08-30 | Lohmann Therapie Syst Lts | Verpackung flächenförmiger Gegenstände mit verbesserter Aufreisseigenschaft |
DE10025644A1 (de) * | 2000-05-24 | 2001-12-06 | Lohmann Therapie Syst Lts | Schmales bandförmiges transdermales therapeutisches System zur Applikation von Wirkstoffen direkt über dem arteriellen oder venösen Gefäßsystem |
CN1462194B (zh) * | 2001-04-24 | 2013-04-24 | 琳得科株式会社 | 口服给药制剂及口服给药制剂保持体 |
US8268333B2 (en) | 2001-04-24 | 2012-09-18 | Lintec Corporation | Orally administered agent and an orally administered agent/supporting substrate complex |
AU2008201149B2 (en) * | 2001-04-24 | 2010-12-09 | Lintec Corporation | A gel-forming composition |
JP4993652B2 (ja) * | 2004-03-31 | 2012-08-08 | リンテック株式会社 | 経口投与剤 |
US6419903B1 (en) * | 2001-08-20 | 2002-07-16 | Colgate Palmolive Company | Breath freshening film |
US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US7666337B2 (en) * | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US7425292B2 (en) * | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20070154527A1 (en) * | 2001-10-12 | 2007-07-05 | Monosoirx, Llc | Topical film compositions for delivery of actives |
US8765167B2 (en) * | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US20100021526A1 (en) * | 2001-10-12 | 2010-01-28 | Monosol Rx, Llc | Ph modulated films for delivery of actives |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20060039958A1 (en) * | 2003-05-28 | 2006-02-23 | Monosolrx, Llc. | Multi-layer films having uniform content |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
ES2735512T3 (es) | 2001-10-12 | 2019-12-19 | Aquestive Therapeutics Inc | Película delgada con heterogeneidad uniforme no autoagregable, proceso para su producción y sistemas de administración de fármacos hechos a partir de la misma |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
AU2003235716A1 (en) | 2002-01-17 | 2003-07-30 | Lts Lohmann Therapie-Systeme Ag | Method for neutralizing or recycling carrier materials for film-like coatings |
JP4448694B2 (ja) * | 2002-01-25 | 2010-04-14 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ウェブ状製品の製造方法および装置 |
US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
WO2003097103A1 (fr) * | 2002-05-16 | 2003-11-27 | Kyukyu Pharmaceutical Co.,Ltd. | Preparations de film rapidement soluble |
DE10224612A1 (de) * | 2002-06-04 | 2003-12-24 | Lohmann Therapie Syst Lts | Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung |
CA2505796C (en) * | 2002-07-22 | 2012-01-03 | Monosolrx Llc | Packaging and dispensing of rapid dissolve dosage form |
US20040120991A1 (en) * | 2002-09-07 | 2004-06-24 | Mars Incorporated | Edible films having distinct regions |
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
SE0302947D0 (sv) * | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
DK1587504T3 (da) * | 2003-01-30 | 2012-07-02 | Monosolrx Llc | Fremgangsmåde til fremstilling af en tynd film omfattende varmefølsomme aktive stoffer |
CA2544776C (en) | 2003-05-28 | 2014-04-15 | Monosolrx Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
WO2005039499A2 (en) | 2003-10-24 | 2005-05-06 | Adhesives Research, Inc. | Rapidly disintegrating film |
JP4931596B2 (ja) | 2003-11-07 | 2012-05-16 | ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー | タバコ組成物 |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US20050186256A1 (en) * | 2004-02-20 | 2005-08-25 | Dihel Deborah L. | Dissolvable film comprising an active ingredient and method of manufacture |
JP2005298471A (ja) * | 2004-03-17 | 2005-10-27 | Lintec Corp | 薬剤の製造方法 |
JP2005289867A (ja) * | 2004-03-31 | 2005-10-20 | Lintec Corp | 経口投与剤 |
US7972589B2 (en) * | 2004-05-17 | 2011-07-05 | Akzo Nobel N.V. | Hair fixative film |
BRPI0514429A8 (pt) * | 2004-08-16 | 2018-04-24 | Imerys Pigments Inc | lama de caulim estabilizada, e, métodos para produzir uma lama de caulim estabilizada, para estabilizar uma lama de caulim, e para melhorar a estabilidade de uma lama de caulim |
US20060062811A1 (en) * | 2004-09-21 | 2006-03-23 | Szymczak Christopher E | Medicinal cooling emulsions |
AU2006206252B2 (en) | 2005-01-19 | 2009-11-05 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
WO2006107390A2 (en) | 2005-04-04 | 2006-10-12 | Kronos Advanced Technologies, Inc. | An electrostatic fluid accelerator for and method of controlling a fluid flow |
WO2006127879A1 (en) * | 2005-05-26 | 2006-11-30 | Duramed Pharmaceuticals, Inc. | Flexible solid dosage forms and methods of making and using the same |
US20060292107A1 (en) * | 2005-06-24 | 2006-12-28 | Mccormick Benjamin W | Solid shaving composition and packaging system |
WO2007056066A2 (en) | 2005-11-04 | 2007-05-18 | Lifescience Plus, Inc. | Bioabsorbable hemostatic gauze |
JP2009523672A (ja) * | 2006-01-20 | 2009-06-25 | モノソル アールエックス リミテッド ライアビリティ カンパニー | フィルムライニングを施した、包装体およびその製法 |
JP2009523808A (ja) * | 2006-01-20 | 2009-06-25 | モノソル アールエックス リミテッド ライアビリティ カンパニー | 活性物質の粘膜投与のためのフィルム包帯 |
US20080152761A1 (en) * | 2006-12-20 | 2008-06-26 | Shiji Shen | Packaging of Food Products with Pullulan Films |
CN101516331A (zh) * | 2006-09-20 | 2009-08-26 | 莫诺索尔克斯有限公司 | 含有抗泡沫调味剂的可食用水溶性膜 |
EP2077824A4 (de) * | 2006-09-29 | 2012-07-18 | Monosol Rx Llc | In folie eingebettete verpackung und herstellungsverfahren dafür |
CA2675356A1 (en) * | 2007-01-12 | 2008-07-24 | Monosol Rx, Llc | High dose film compositions and methods of preparation |
US20090011115A1 (en) * | 2007-03-13 | 2009-01-08 | Foss Carter D | Edible Pullulan Films Containing Flavoring |
WO2008127902A2 (en) * | 2007-04-12 | 2008-10-23 | Tate & Lyle Ingredients Americas, Inc. | Pullulan film containing sweetener |
MX2010003928A (es) | 2007-10-11 | 2010-09-10 | Philip Morris Prod | Producto de tabaco sin humo. |
US9125434B2 (en) | 2007-10-11 | 2015-09-08 | Philip Morris Products S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
US20090098192A1 (en) * | 2007-10-11 | 2009-04-16 | Fuisz Richard C | Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same |
DE102008023345B4 (de) | 2008-05-13 | 2014-12-04 | Lts Lohmann Therapie-Systeme Ag | Filmförmige Zubereitung mit öligen Substanzen zur oralen Verabreichung |
US9265779B2 (en) | 2008-05-13 | 2016-02-23 | Lts Lohmann Therapie-Systeme Ag | Method of using a film-shaped preparation comprising oily substances for oral administration |
WO2010064988A1 (en) * | 2008-12-04 | 2010-06-10 | Swedish Pharma Ab | Bioadhesive patch |
US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
WO2011156711A1 (en) | 2010-06-10 | 2011-12-15 | Schobel Alexander M | Nanoparticle film delivery systems |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US8241661B1 (en) | 2011-06-24 | 2012-08-14 | Fuisz Richard C | Biocompatible film with variable cross-sectional properties |
DE102011088909A1 (de) * | 2011-08-12 | 2013-02-14 | Labtec Gmbh | Verfahren zur Herstellung und Kontrolle von oralen Wirkstoff-Filmen |
CN104736133B (zh) | 2012-10-17 | 2020-07-10 | 宝洁公司 | 用于递送口腔护理活性物质的条带以及施用口腔护理活性物质的方法 |
US9303918B2 (en) | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
US20140275194A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Films and drug delivery systems for rizatriptan |
WO2014145699A1 (en) | 2013-03-15 | 2014-09-18 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
DE102016105889A1 (de) * | 2016-03-31 | 2017-10-05 | Amw Gmbh | Transdermales Applikationssystem mit Informationsschicht |
CN113786407A (zh) | 2016-01-26 | 2021-12-14 | 细胞内治疗公司 | 有机化合物 |
KR20230003461A (ko) | 2016-03-25 | 2023-01-05 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
BR112018072539A2 (pt) | 2016-05-05 | 2019-03-26 | Aquestive Therapeutics, Inc. | composições de epinefrina de administração aumentada |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
US11173114B1 (en) | 2020-07-10 | 2021-11-16 | Nova Thin Film Pharmaceuticals Llc | Method and system for manufacturing and oral soluble films and oral soluble films made by thereby |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB139077A (en) * | 1919-05-15 | 1920-02-26 | Edmund Morse Pond | Improvements in or pertaining to plasters |
GB1061557A (en) * | 1964-04-01 | 1967-03-15 | Ashe Chemical Ltd | New impregnated or coated films |
GB1142325A (en) * | 1965-05-14 | 1969-02-05 | Higham Stanley Russell | Means for administering drugs |
JPS5154917A (ja) * | 1974-11-01 | 1976-05-14 | Toppan Printing Co Ltd | Seizaihoho |
DE2746414A1 (de) * | 1977-10-15 | 1979-04-26 | Gerlach Eduard Chem Fab | Mittel zum dosieren von stoffen und verfahren zu seiner herstellung |
JPH05154648A (ja) * | 1991-05-28 | 1993-06-22 | Yosetsu Gijutsu Kenkyusho:Kk | ワークのはんだ付け方法 |
-
1986
- 1986-10-07 EP EP86906303A patent/EP0283474A1/de active Pending
- 1986-10-07 DE DE8686113919T patent/DE3676626D1/de not_active Expired - Lifetime
- 1986-10-07 US US07/060,689 patent/US4849246A/en not_active Expired - Lifetime
- 1986-10-07 WO PCT/EP1986/000571 patent/WO1987002241A1/de not_active Application Discontinuation
- 1986-10-07 AU AU65417/86A patent/AU6541786A/en not_active Abandoned
- 1986-10-07 EP EP86113919A patent/EP0219762B1/de not_active Expired - Lifetime
- 1986-10-07 JP JP61505689A patent/JPS63501794A/ja active Pending
- 1986-10-07 ES ES86113919T patent/ES2019275B3/es not_active Expired - Lifetime
- 1986-10-07 AT AT86113919T patent/ATE59289T1/de not_active IP Right Cessation
- 1986-10-09 CA CA000520214A patent/CA1275046A/en not_active Expired - Fee Related
-
1990
- 1990-12-28 GR GR90400991T patent/GR3001238T3/el unknown
Non-Patent Citations (1)
Title |
---|
See references of WO8702241A1 * |
Also Published As
Publication number | Publication date |
---|---|
US4849246A (en) | 1989-07-18 |
CA1275046A (en) | 1990-10-09 |
AU6541786A (en) | 1987-05-05 |
ATE59289T1 (de) | 1991-01-15 |
ES2019275B3 (es) | 1991-06-16 |
DE3676626D1 (de) | 1991-02-07 |
WO1987002241A1 (en) | 1987-04-23 |
JPS63501794A (ja) | 1988-07-21 |
GR3001238T3 (en) | 1992-07-30 |
EP0219762A1 (de) | 1987-04-29 |
EP0219762B1 (de) | 1990-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0219762B1 (de) | Verfahren zur Herstellung einer Darreichungs- und Dosierungsform für Arzneimittel-Wirkstoffe, Reagentien oder andere Wirkstoffe | |
EP0259749B1 (de) | Darreichungs- und Dosierungsform für Arzneimittelwirkstoffe, Reagentien oder dergleichen sowie Verfahren zu deren Herstellung | |
DE4018247C2 (de) | ||
DE1492107C3 (de) | Verfahren zur Herstellung einer Acetylsalicylsauretablette | |
EP0949925B1 (de) | Flache arzneizubereitung zur applikation und freisetzung von buprenorphin oder einer pharmakologisch vergleichbaren substanz in der mundhöhle und verfahren zu ihrer herstellung | |
DE69727922T2 (de) | Schnell zerfallende orale dosierungsform | |
DE4341442C2 (de) | Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung | |
DE19715794C1 (de) | Laminare Arzneiform und Verfahren zu ihrer Herstellung | |
DE2656387C2 (de) | Verfahren und Vorrichtung zum Herstellen fester pharmazeutischer Einheitsdosierungsformen | |
DE2932615C2 (de) | Verfahren zum Herstellen fester pharmazeutischer Einheitsdosierungsformen | |
WO2001035934A1 (de) | Filmförmige zubereitung zur biphasigen freisetzung pharmakologisch wirksamer oder anderer substanzen | |
DE4140192C2 (de) | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen | |
WO2000010539A1 (de) | Folienförmige wirkstoffträger | |
EP2741734B1 (de) | Verfahren zur herstellung und kontrolle von oralen wirkstoff-filmen | |
WO2019101800A2 (de) | Taschenförmige oral auflösende filme mit hoher wirkstoffbeladung | |
WO2022195044A1 (de) | Gerollte oral thin films mit hoher wirkstoffbeladung | |
DE202022100544U1 (de) | Neue orale Streifen- oder Dünnfilmform von Diclofenac-Natrium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 19880408 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
XX | Miscellaneous (additional remarks) |
Free format text: 230189. |
|
XX | Miscellaneous (additional remarks) |
Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 86113919.4/0219762 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 230189. |
|
XX | Miscellaneous (additional remarks) |
Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 86113919.4/0219762 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 230189. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SCHMIDT, WOLFGANG |